MSFT   178.83 (-1.51%)
GOOGL   1,412.09 (-0.65%)
NVDA   331.44 (-4.95%)
CGC   19.34 (-3.35%)
BABA   199.70 (-1.00%)
TSLA   808.90 (-1.22%)
T   31.89 (+3.47%)
ACB   15.50 (-0.70%)
GILD   73.88 (+0.96%)
BAC   25.34 (+4.37%)
MSFT   178.83 (-1.51%)
GOOGL   1,412.09 (-0.65%)
NVDA   331.44 (-4.95%)
CGC   19.34 (-3.35%)
BABA   199.70 (-1.00%)
TSLA   808.90 (-1.22%)
T   31.89 (+3.47%)
ACB   15.50 (-0.70%)
GILD   73.88 (+0.96%)
BAC   25.34 (+4.37%)
MSFT   178.83 (-1.51%)
GOOGL   1,412.09 (-0.65%)
NVDA   331.44 (-4.95%)
CGC   19.34 (-3.35%)
BABA   199.70 (-1.00%)
TSLA   808.90 (-1.22%)
T   31.89 (+3.47%)
ACB   15.50 (-0.70%)
GILD   73.88 (+0.96%)
BAC   25.34 (+4.37%)
MSFT   178.83 (-1.51%)
GOOGL   1,412.09 (-0.65%)
NVDA   331.44 (-4.95%)
CGC   19.34 (-3.35%)
BABA   199.70 (-1.00%)
TSLA   808.90 (-1.22%)
T   31.89 (+3.47%)
ACB   15.50 (-0.70%)
GILD   73.88 (+0.96%)
BAC   25.34 (+4.37%)
Log in

NASDAQ:OPRXOptimizeRx Stock Price, Forecast & News

$12.08
-0.21 (-1.71 %)
(As of 05/27/2020 10:30 AM ET)
Add
Compare
Today's Range
$11.87
Now: $12.08
$12.36
50-Day Range
$8.46
MA: $9.73
$11.59
52-Week Range
$6.50
Now: $12.08
$17.24
Volume4,004 shs
Average Volume98,833 shs
Market Capitalization$176.90 million
P/E RatioN/A
Dividend YieldN/A
Beta0.21
OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company's cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care. Its products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems to search, print, or electronically dispense directly to patients, as well as for a network of pharmacies; and Brand and Clinical Messaging that includes various brand awareness and clinical messaging services consisting of brand awareness messages, reminder ads, clinical messages, and unbranded messages targeted by specialty, diagnostic code, and other criteria. The company's products and applications also comprise brand support services, which focuses on educating and working with pharmaceutical manufacturers on identifying, formulating, and implementing new eRx media strategies, including drug file integration, sales force training, and strategy development services for promoting their products. It also operates Mobile Health Messenger platform that provides interactive health messaging for enhanced medication adherence, care coordination, and patient engagement; and HIPAA-compliant, an automated and mobile messaging platform that allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance. OptimizeRx Corporation is based in Rochester, Michigan.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.11 out of 5 stars


Industry, Sector and Symbol

Industry Business services, not elsewhere classified
Sub-IndustryN/A
SectorComputer and Technology
Current SymbolNASDAQ:OPRX
CUSIPN/A
CIKN/A
Phone248-651-6558

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$24.60 million
Book Value$2.98 per share

Profitability

Net Income$-3,140,000.00

Miscellaneous

Employees37
Market Cap$176.90 million
Next Earnings Date8/5/2020 (Estimated)
OptionableNot Optionable

Receive OPRX News and Ratings via Email

Sign-up to receive the latest news and ratings for OPRX and its competitors with MarketBeat's FREE daily newsletter.

OptimizeRx (NASDAQ:OPRX) Frequently Asked Questions

How has OptimizeRx's stock been impacted by COVID-19 (Coronavirus)?

OptimizeRx's stock was trading at $7.51 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, OPRX shares have increased by 60.8% and is now trading at $12.0750. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of OptimizeRx?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptimizeRx in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for OptimizeRx.

When is OptimizeRx's next earnings date?

OptimizeRx is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for OptimizeRx.

How were OptimizeRx's earnings last quarter?

OptimizeRx Co. (NASDAQ:OPRX) issued its quarterly earnings results on Monday, May, 4th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by $0.03. The company earned $7.59 million during the quarter, compared to the consensus estimate of $7.10 million. OptimizeRx had a negative net margin of 19.86% and a negative return on equity of 11.18%. View OptimizeRx's earnings history.

What price target have analysts set for OPRX?

2 brokerages have issued 12 month price targets for OptimizeRx's shares. Their forecasts range from $22.00 to $22.00. On average, they anticipate OptimizeRx's stock price to reach $22.00 in the next year. This suggests a possible upside of 82.2% from the stock's current price. View analysts' price targets for OptimizeRx.

Has OptimizeRx been receiving favorable news coverage?

News headlines about OPRX stock have trended somewhat negative this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. OptimizeRx earned a news impact score of -1.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutOptimizeRx.

Who are some of OptimizeRx's key competitors?

What other stocks do shareholders of OptimizeRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OptimizeRx investors own include Bank of Hawaii (BOH), InterDigital Wireless (IDCC), NVIDIA (NVDA), Stag Industrial (STAG), Amgen (AMGN), Verizon Communications (VZ), Alibaba Group (BABA), Crispr Therapeutics (CRSP), Etsy (ETSY) and Exelixis (EXEL).

Who are OptimizeRx's key executives?

OptimizeRx's management team includes the following people:
  • Mr. William J. Febbo, CEO & Director (Age 50)
  • Ms. Miriam J. Paramore, Pres (Age 56)
  • Mr. Douglas P. Baker, Chief Financial Officer (Age 62)
  • Mr. Terence J. Hamilton, Sr. VP of Sales (Age 54)
  • Mr. James Brooks, Consultant (Age 50)

What is OptimizeRx's stock symbol?

OptimizeRx trades on the NASDAQ under the ticker symbol "OPRX."

Who are OptimizeRx's major shareholders?

OptimizeRx's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.39%), Park West Asset Management LLC (4.65%), Wasatch Advisors Inc. (4.52%), Wolverine Asset Management LLC (2.11%), P.A.W. Capital Corp (2.05%) and State Street Corp (1.67%). Company insiders that own OptimizeRx stock include Awm Investment Company, Inc, Douglas P Baker, Ellen O'connor Vos, Gus D Halas, Miriam J Paramore, Patrick D Spangler and William J Febbo. View institutional ownership trends for OptimizeRx.

Which major investors are selling OptimizeRx stock?

OPRX stock was sold by a variety of institutional investors in the last quarter, including Wolverine Asset Management LLC, Park West Asset Management LLC, UBS Group AG, Atlantic Trust LLC, Taylor Wealth Management Partners, Perkins Capital Management Inc., BlackRock Inc., and Bank of New York Mellon Corp. View insider buying and selling activity for OptimizeRx.

Which major investors are buying OptimizeRx stock?

OPRX stock was bought by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Blair William & Co. IL, Bullseye Asset Management LLC, P.A.W. Capital Corp, Geode Capital Management LLC, Wells Fargo & Company MN, Advisor Group Holdings Inc., and State Street Corp. Company insiders that have bought OptimizeRx stock in the last two years include Ellen O'connor Vos, Gus D Halas, Miriam J Paramore, Patrick D Spangler, and William J Febbo. View insider buying and selling activity for OptimizeRx.

How do I buy shares of OptimizeRx?

Shares of OPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is OptimizeRx's stock price today?

One share of OPRX stock can currently be purchased for approximately $12.08.

How big of a company is OptimizeRx?

OptimizeRx has a market capitalization of $176.90 million and generates $24.60 million in revenue each year. The company earns $-3,140,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. OptimizeRx employs 37 workers across the globe.

What is OptimizeRx's official website?

The official website for OptimizeRx is www.optimizerx.com.

How can I contact OptimizeRx?

OptimizeRx's mailing address is 400 WATER STREET SUITE 200, ROCHESTER MI, 48307. The company can be reached via phone at 248-651-6558 or via email at [email protected]

This page was last updated on 5/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.